Guizhou Xinbang Pharmaceutical Co., Ltd. (SHE:002390)
China · Delayed Price · Currency is CNY 3.320
+0.040 (1.22%)
Feb 3, 2026, 3:04 PM CST
SHE:002390 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 5,701 | 6,000 | 6,436 | 6,331 | 6,441 | 5,819 |
Other Revenue | 32.17 | 32.17 | 24.98 | 19.36 | 30.76 | 26.18 |
| 5,733 | 6,032 | 6,461 | 6,350 | 6,472 | 5,846 | |
Revenue Growth (YoY) | -7.57% | -6.63% | 1.75% | -1.88% | 10.71% | -12.16% |
Cost of Revenue | 4,798 | 5,000 | 5,240 | 5,133 | 5,119 | 4,594 |
Gross Profit | 934.87 | 1,032 | 1,221 | 1,217 | 1,352 | 1,252 |
Selling, General & Admin | 609.72 | 669.9 | 737.84 | 814.14 | 766.62 | 775.52 |
Research & Development | 5.05 | 4.59 | 4.67 | 1.21 | 1.94 | 10.56 |
Other Operating Expenses | 38.41 | 25.01 | 22.57 | 28.19 | 28.7 | 23.91 |
Operating Expenses | 685.05 | 749.07 | 830.01 | 884.14 | 823.94 | 847.94 |
Operating Income | 249.83 | 282.84 | 391.05 | 332.82 | 528.56 | 403.64 |
Interest Expense | -21.17 | -23.54 | -39.7 | -51.79 | -100.19 | -99.61 |
Interest & Investment Income | 9.43 | 10.76 | 22.13 | 50.97 | 17.92 | 15.37 |
Currency Exchange Gain (Loss) | -0 | -0 | 0 | 0 | -0 | 2.3 |
Other Non Operating Income (Expenses) | -26.14 | -18.96 | 11.01 | -22.76 | -4.47 | -23.5 |
EBT Excluding Unusual Items | 211.95 | 251.1 | 384.49 | 309.25 | 441.82 | 298.19 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -16.97 |
Gain (Loss) on Sale of Assets | -2.18 | -2.29 | 0.02 | -0 | -0.42 | -1.7 |
Asset Writedown | -1.11 | -1.11 | -0.56 | -2.13 | -4.04 | -2.65 |
Other Unusual Items | -62.2 | -62.2 | 12.08 | 6.28 | -16.23 | -9.42 |
Pretax Income | 146.46 | 185.5 | 396.02 | 313.39 | 421.12 | 267.46 |
Income Tax Expense | 22.73 | 29.81 | 42.25 | 45.14 | 47.17 | 46.88 |
Earnings From Continuing Operations | 123.73 | 155.69 | 353.77 | 268.26 | 373.96 | 220.58 |
Minority Interest in Earnings | -46.61 | -54.31 | -66.54 | -43.88 | -101.09 | -47.05 |
Net Income | 77.12 | 101.38 | 287.23 | 224.37 | 272.87 | 173.52 |
Net Income to Common | 77.12 | 101.38 | 287.23 | 224.37 | 272.87 | 173.52 |
Net Income Growth | -64.50% | -64.70% | 28.02% | -17.77% | 57.25% | -26.57% |
Shares Outstanding (Basic) | 2,022 | 2,028 | 1,915 | 1,870 | 1,819 | 1,577 |
Shares Outstanding (Diluted) | 2,022 | 2,028 | 1,915 | 1,870 | 1,819 | 1,577 |
Shares Change (YoY) | 7.11% | 5.89% | 2.41% | 2.79% | 15.32% | 0.14% |
EPS (Basic) | 0.04 | 0.05 | 0.15 | 0.12 | 0.15 | 0.11 |
EPS (Diluted) | 0.04 | 0.05 | 0.15 | 0.12 | 0.15 | 0.11 |
EPS Growth | -66.86% | -66.67% | 25.00% | -20.00% | 36.36% | -26.67% |
Free Cash Flow | 571.58 | 510.1 | 654.84 | 432.02 | 204.21 | 604.02 |
Free Cash Flow Per Share | 0.28 | 0.25 | 0.34 | 0.23 | 0.11 | 0.38 |
Dividend Per Share | 0.060 | 0.060 | 0.060 | 0.060 | 0.060 | - |
Dividend Growth | -33.33% | - | - | - | - | - |
Gross Margin | 16.31% | 17.11% | 18.90% | 19.16% | 20.90% | 21.41% |
Operating Margin | 4.36% | 4.69% | 6.05% | 5.24% | 8.17% | 6.91% |
Profit Margin | 1.34% | 1.68% | 4.45% | 3.53% | 4.22% | 2.97% |
Free Cash Flow Margin | 9.97% | 8.46% | 10.13% | 6.80% | 3.16% | 10.33% |
EBITDA | 442.72 | 491.06 | 619.72 | 567.89 | 767.42 | 635.29 |
EBITDA Margin | 7.72% | 8.14% | 9.59% | 8.94% | 11.86% | 10.87% |
D&A For EBITDA | 192.89 | 208.22 | 228.67 | 235.06 | 238.86 | 231.65 |
EBIT | 249.83 | 282.84 | 391.05 | 332.82 | 528.56 | 403.64 |
EBIT Margin | 4.36% | 4.69% | 6.05% | 5.24% | 8.17% | 6.91% |
Effective Tax Rate | 15.52% | 16.07% | 10.67% | 14.40% | 11.20% | 17.53% |
Revenue as Reported | 5,733 | 6,032 | 6,461 | 6,350 | 6,472 | 5,846 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.